Biochemistry and Cellular & Molecular Biology, Georgetown University Medical Center, Washington, 20007, District of Columbia.
J Cell Biochem. 2018 Jan;119(1):134-140. doi: 10.1002/jcb.26195. Epub 2017 Jul 11.
CRISPR/Cas gene editing technologies have emerged as powerful tools in the study of oncogenic transformation. The system's specificity, versatility, and ease of implementation allow researchers to identify important molecular markers and pathways which grant cancers stem cell like properties. This technology has already been applied to researching specific cancers, but has seen restricted therapeutic applications due to inherent ethical and technical limitations. Active development and adaptation of the CRISPR/Cas system has produced new methods to take advantage of both non-homologous end joining and homologous recombination repair mechanisms in attempts to remedy these limitations and improve the versatility of gene edits that can be created. Nonetheless, until issues with specificity and in vivo efficiency are resolved, utilization of CRISPR/Cas systems would be best employed in the modeling and study of various cancer genes. While it may have potential therapeutic applications to targeted cancer therapies in the future, presently CRISPR/Cas is a remarkable technique that can be utilized for easy and efficient gene editing when it comes to cancer research. J. Cell. Biochem. 119: 134-140, 2018. © 2017 Wiley Periodicals, Inc.
CRISPR/Cas 基因编辑技术已成为研究致癌转化的有力工具。该系统的特异性、多功能性和易于实施性,使研究人员能够识别赋予癌症干细胞样特性的重要分子标记物和途径。该技术已经应用于特定癌症的研究,但由于固有的伦理和技术限制,其治疗应用受到限制。CRISPR/Cas 系统的积极开发和调整产生了新的方法,利用非同源末端连接和同源重组修复机制,试图克服这些限制并提高可创建的基因编辑的多功能性。尽管如此,在解决特异性和体内效率问题之前,最好将 CRISPR/Cas 系统用于各种癌症基因的建模和研究。虽然它将来可能有针对癌症靶向治疗的潜在治疗应用,但目前 CRISPR/Cas 是一种非常出色的技术,可用于癌症研究中的简便高效的基因编辑。细胞生化学杂志 119: 134-140, 2018。© 2017 Wiley Periodicals, Inc.